Oxford Nanopore Technologies (ONT) Stifel 2026 Healthcare Conference 2026 summary

Platform differentiation

• Single-molecule nanopore sensing reads DNA, RNA and proteins through electrical signals decoded with machine learning; the platform is miniaturizable and delivers real-time information.

• Native sequencing avoids copying, cutting and amplification, preserving methylation and other molecular features while supporting any read length, from structural variants to short-read information.

• Commercialized for 12 years, with revenue growth consistently above 20% annually and GBP 250 million in revenue last year.

Market focus and research outlook

• Revenue mix: research and government 65%, clinical ~15%, biopharma 8%, with the balance from industrial markets; a 450-person commercial workforce supports adoption.

• Strategy narrows 47 sequencing end markets to ~15 target areas based on technology differentiation and ease of commercialization; priority applications include infectious disease, rare disease and oncology.

• Research grew 5% in H1, including ~$10 million of prior-year contracts that did not repeat; excluding those roll-offs, growth was high teens, with improvement expected in H2.

• Research is expected to sustain low-teens growth through 2030 despite weak end markets, supported by early adoption and perceived value over conventional technologies.

Applied-market opportunities

• Clinical opportunity estimated at GBP 10 billion; go-to-market plan focuses on selected use cases and partnerships for tertiary analysis and sample-prep automation, while retaining sequencing, basecalling and sample-prep elements.

• mRNA quality-control workflow consolidates tests for identity, integrity and purity; the launched identity test replaces Sanger and another technology, with additional CQAs planned to replace more tests.

• mRNA QC can reduce testing from potentially a month on conventional platforms to a few days; Lonza has a GMP-qualified test, while direct engagement with manufacturers is also underway.

• Sterility-testing workflow aims to shorten batch-release time by about a week; 20 companies are evaluating the technology across mRNA and other applications, including sterility testing.

• Clinical growth is expected to extend beyond 2030; roadmap priorities include accuracy in selected applications, higher-throughput barcoding, communicating methylation value, and strengthening bioinformatics and analysis partnerships.